Eton Pharmaceuticals (ETON) 10% Holder Opaleye Management Sells Shares

What Happened
Opaleye Management, Inc. (reported as a 10% owner) sold a total of 28,315 shares of Eton Pharmaceuticals (ETON) in transactions on July 14, 2026. The filing reports two dispositions: 15,000 shares for $563,147 and 13,315 shares for $499,886, for combined proceeds of approximately $1,063,033. The reported weighted-average price was $37.54 per share (sales executed across multiple prices).

Key Details

• Transaction date: 2026-07-14 (filed with the SEC on 2026-07-16). Filing appears timely.
• Sales: 15,000 shares ($563,147) and 13,315 shares ($499,886); total 28,315 shares for ~$1,063,033.
• Price detail: weighted average $37.54; actual trades ranged $37.0152 to $37.9148 (footnote F3).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Footnotes of note:
  • F1/F2: Some shares are held directly by Opaleye funds/accounts; Opaleye Management is the investment/portfolio manager for those vehicles.
  • F4: Opaleye Management disclaims beneficial ownership except to the extent of any pecuniary interest.
• Transaction code: S (sale).

Context
This filing reflects institutional selling by a 10% holder/manager rather than an individual executive. Such sales can reflect portfolio management decisions and do not, by themselves, indicate company-specific insider sentiment. The filing includes the manager’s disclaimer that it may be deemed to beneficially own securities held by the funds/accounts it manages, but disclaims ownership beyond any pecuniary interest.